Ravicti

The dosage of Glycerol Phenylbutyrate is highly individualized and must be calculated by a specialist in metabolic diseases. For adults switching from sodium phenylbutyrate to Glycerol Phenylbutyrate, the initial dose is typically calculated based on the previous dose of sodium phenylbutyrate. The conversion ratio is approximately 0.86 mL of Glycerol Phenylbutyrate for every 1 gram of sodium phenylbutyrate. For patients who have never taken phenylbutyrate (treatment-naive), the dose is usually based on Body Surface Area (BSA). The typical starting range is 4.5 mL/m²/day to 11.2 mL/m²/day (approximately 5 to 12.4 grams/m²/day). The total daily dose is divided into equal amounts and given with each meal or feeding (e.g., 3 to 6 times per day).

Glycerol Phenylbutyrate is approved for use in pediatric patients of all ages, including neonates. Like adults, pediatric dosing is based on Body Surface Area (BSA) or a conversion from sodium phenylbutyrate.

• Infants and Children: The dose is usually between 4.5 and 11.2 mL/m²/day. Because children grow rapidly, the dosage must be adjusted frequently based on weight and BSA changes.
• Neonates (0-28 days): Dosing in newborns requires extreme caution and frequent monitoring of ammonia levels, as their metabolic pathways are still developing.

Renal Impairment

There are no specific dosage adjustment guidelines for patients with renal (kidney) impairment; however, since the drug's metabolites are excreted by the kidneys, healthcare providers will monitor these patients closely. If kidney function is significantly decreased, the clearance of phenylacetylglutamine (PAGN) may be reduced.

Hepatic Impairment

Patients with mild to moderate hepatic (liver) impairment (Child-Pugh Class A or B) may require lower starting doses. The liver is responsible for converting phenylbutyrate to phenylacetic acid (PAA). In patients with severe hepatic impairment, the conversion may be inefficient, leading to lower efficacy or an accumulation of metabolites. Frequent monitoring of plasma ammonia and PAA levels is mandatory.

Elderly Patients

Clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function.

• Administration: The liquid should be measured accurately using an oral syringe provided by the pharmacy. It can be taken directly by mouth or mixed with a small amount of soft food (like applesauce or pudding) or formula.
• With Food: Glycerol Phenylbutyrate must be taken with meals or feedings. This helps the drug work more effectively by processing the nitrogen from the protein in the food.
• Feeding Tubes: If the patient has a G-tube or NG-tube, the medication can be administered through the tube. The tube should be flushed with water before and after administration to ensure the full dose is received.
• Storage: Store at room temperature (20°C to 25°C or 68°F to 77°F). Do not freeze. Keep the bottle tightly closed.

If a dose is missed, it should be taken as soon as possible with food. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. Do not 'double up' on doses to make up for a missed one. Consistent dosing is critical to maintaining stable ammonia levels.

Signs of overdose may include symptoms of phenylacetic acid (PAA) toxicity, such as severe headache, dizziness, lightheadedness, confusion, sleepiness, or a 'mousy' body odor. In the event of a suspected overdose, contact a poison control center or seek emergency medical attention immediately. Treatment is generally supportive and may include temporary discontinuation of the drug.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Frequent blood tests are required to ensure the dose is correct for your metabolic needs.

Common side effects associated with Glycerol Phenylbutyrate can vary between adults and children. In clinical trials, the most frequently reported adverse reactions (occurring in more than 10% of patients) included:

• Diarrhea: This is often mild but can be persistent. It occurs as the digestive system adjusts to the triglyceride liquid.
• Flatulence and Bloating: Many patients experience increased gas or a feeling of fullness in the abdomen.
• Nausea and Vomiting: These symptoms are common, especially when starting the medication or increasing the dose.
• Headache: Often described as a dull ache, which may be related to the medication itself or fluctuations in ammonia levels.
• Decreased Appetite: Some patients, particularly children, may show less interest in food.

These side effects occur in a smaller percentage of the population but are still clinically significant:

• Abdominal Pain: Upper or lower abdominal discomfort or cramping.
• Fatigue: A general feeling of tiredness or lack of energy.
• Dizziness: A sensation of spinning or lightheadedness.
• Skin Rash: Some patients develop mild acne or itchy skin (pruritus).
• Amenorrhea or Irregular Menstruation: Changes in the menstrual cycle have been reported in some female patients.
• Mousy or Body Odor: This is caused by the excretion of the metabolite phenylacetic acid (PAA) through sweat.

• Severe Allergic Reactions: Though rare, some patients may experience hives, swelling of the face or throat, or difficulty breathing.
• Hypokalemia: Low potassium levels in the blood, which can cause muscle weakness or heart rhythm issues.
• Increased Liver Enzymes: Asymptomatic elevations in AST or ALT levels.

> Warning: Stop taking Glycerol Phenylbutyrate and call your doctor immediately if you experience any of these symptoms, as they may indicate a medical emergency or drug toxicity.

• Signs of PAA Toxicity: Phenylacetic acid (PAA) is a metabolite of the drug. If levels become too high, it can cause neurological symptoms. Seek help for: extreme sleepiness, confusion, 'brain fog,' severe headache, or a feeling of being 'drunk' without drinking alcohol.
• Signs of Hyperammonemia (Ammonia Spike): This drug does not prevent all ammonia spikes. Seek emergency care for: vomiting, lethargy (extreme sleepiness), irritability, combativeness, or seizures. This is a medical emergency.
• Severe Abdominal Pain: Could indicate a complication like pancreatitis (inflammation of the pancreas), although this is not common.

Long-term use of Glycerol Phenylbutyrate requires careful monitoring. Potential long-term considerations include:

• Nutritional Deficiencies: Because patients must remain on a protein-restricted diet, there is a risk of deficiencies in essential amino acids, vitamins, and minerals. Regular nutritional assessments are required.
• Growth Effects in Children: While the drug itself does not typically stunt growth, the underlying urea cycle disorder and the necessary protein restriction can impact a child's height and weight gain. Close monitoring by a pediatric metabolic specialist is essential.
• Neurodevelopmental Monitoring: Patients with UCDs are at risk for developmental delays. Long-term treatment aims to minimize this risk by keeping ammonia levels stable.

No FDA black box warnings currently exist for Glycerol Phenylbutyrate. However, the FDA emphasizes that this drug is not for acute hyperammonemia and requires specialized management.

Report any unusual symptoms to your healthcare provider. Side effects are often manageable with dose adjustments or changes in how the medication is administered (e.g., taking it with different foods).

Glycerol Phenylbutyrate is a chronic maintenance medication. It is not designed to treat a 'hyperammonemic crisis' (a sudden, dangerous rise in ammonia). If a patient shows signs of high ammonia, such as confusion, vomiting, or extreme lethargy, they must be taken to an emergency room immediately for intravenous treatment. Patients must strictly adhere to their prescribed low-protein diet while taking this medication. Failure to follow the diet can lead to treatment failure even if the medication is taken correctly.

No FDA black box warnings for Glycerol Phenylbutyrate. However, the drug label contains significant warnings regarding its use in specific populations and the risk of metabolite toxicity.

• PAA Toxicity Risk: The metabolite phenylacetic acid (PAA) can build up in the body, especially in patients with liver disease. High levels of PAA are associated with neurological symptoms like somnolence (sleepiness) and confusion. If these symptoms occur, the dose may need to be reduced.
• Pancreatic Insufficiency or Intestinal Malabsorption: Because Glycerol Phenylbutyrate requires pancreatic lipases to work, patients with conditions like cystic fibrosis or chronic pancreatitis may not absorb the drug effectively. This could lead to poorly controlled ammonia levels.
• Infection and Stress: Common illnesses (like the flu or a cold), surgery, or emotional stress can trigger a rise in ammonia levels. During these times, the body breaks down its own muscle protein, releasing nitrogen. Patients and caregivers must have an 'emergency protocol' provided by their doctor for these situations.
• Neurotoxicity: In animal studies, high doses of PAA were associated with brain damage in developing animals. While this has not been clearly established in humans, it underscores the need for precise dosing in infants.

Patients taking Glycerol Phenylbutyrate require frequent laboratory monitoring, including:

• Plasma Ammonia: To ensure the drug is maintaining safe levels.
• Plasma Amino Acids: Specifically glutamine, as high glutamine levels can be a precursor to high ammonia.
• PAA and PAGN Levels: To monitor for potential toxicity and to ensure the drug is being metabolized correctly (the PAA/PAGN ratio).
• Liver and Kidney Function Tests: To ensure the organs responsible for processing and excreting the drug are functioning well.

Glycerol Phenylbutyrate may cause dizziness or sleepiness in some patients. Patients should not drive or operate heavy machinery until they know how the medication affects them, especially during the initial dosing phase or after a dose increase.

Alcohol should be avoided. Alcohol can interfere with the liver's ability to process medications and can also trigger metabolic instability in patients with urea cycle disorders.

Glycerol Phenylbutyrate must not be stopped suddenly. Discontinuing the medication will lead to a rapid and dangerous rise in ammonia levels, which can cause permanent brain damage, coma, or death. Any changes to the treatment plan must be made under the strict supervision of a metabolic specialist.

> Important: Discuss all your medical conditions with your healthcare provider before starting Glycerol Phenylbutyrate. Ensure you have a clear plan for what to do during 'sick days' when ammonia levels are more likely to rise.

There are no drugs that are strictly 'contraindicated' in the sense of causing an immediate lethal reaction, but certain drugs are strongly discouraged because they directly counteract the purpose of Glycerol Phenylbutyrate or increase the risk of toxicity.

• Corticosteroids (e.g., Prednisone, Dexamethasone): Corticosteroids cause the breakdown of body protein (catabolism). This releases a large amount of nitrogen into the blood, which can overwhelm the medication and lead to high ammonia levels. If a patient must take steroids, they require extremely close monitoring.
• Valproic Acid (Depakote): This anti-seizure medication is known to increase blood ammonia levels. Using valproic acid in a patient with a urea cycle disorder is generally avoided as it can worsen the underlying condition.
• Haloperidol: Some studies suggest that haloperidol can increase ammonia levels and should be used with caution.
• Probenecid: This medication, often used for gout, can interfere with the kidneys' ability to excrete the metabolite PAGN. This can lead to an accumulation of PAA in the blood, increasing the risk of neurotoxicity.

• Lipase Inhibitors (e.g., Orlistat): Since Glycerol Phenylbutyrate requires pancreatic lipases to be broken down and absorbed, medications that inhibit lipases will prevent the drug from working. This would lead to a lack of efficacy and a rise in ammonia.
• CYP Enzyme Inducers/Inhibitors: While PAA metabolism is not primarily driven by the CYP450 system, other medications that affect liver enzymes may subtly alter the rate of drug metabolism.

• Protein Intake: The most significant 'interaction' is with dietary protein. The dose of Glycerol Phenylbutyrate is calculated based on a specific amount of daily protein intake. If a patient suddenly increases their protein intake (e.g., eating a large steak), the medication will not be able to handle the extra nitrogen.
• High-Fat Meals: While the drug is a triglyceride and should be taken with food, extremely high-fat meals might slightly delay the absorption process, though this is usually not clinically significant.

• Amino Acid Supplements: Many UCD patients take specific amino acid supplements (like Arginine or Citrulline). These are necessary and are not 'interactions' in a negative sense, but the doses must be balanced.
• St. John's Wort: May affect liver metabolism and should be avoided unless cleared by a specialist.

Glycerol Phenylbutyrate does not typically interfere with standard laboratory tests, but it will significantly affect the results of specialized metabolic tests, such as urinary organic acid analysis (showing high levels of PAGN) and plasma amino acid profiles.

For each major interaction, the management strategy usually involves more frequent monitoring of ammonia levels and potential dose adjustments of either Glycerol Phenylbutyrate or the interacting medication.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Even over-the-counter cold medicines can sometimes contain ingredients that are not ideal for patients with metabolic disorders.

• Known Hypersensitivity: Glycerol Phenylbutyrate is strictly contraindicated in patients who have shown a hypersensitivity (severe allergy) to phenylbutyrate or any component of the formulation. Symptoms of a reaction may include anaphylaxis, swelling of the tongue or throat, and severe rash.
• Acute Hyperammonemia: This medication must NEVER be used as the sole treatment for acute hyperammonemic coma or crisis. In these situations, the patient requires rapid-acting intravenous medications (like Ammonul) or hemodialysis to remove ammonia quickly. Glycerol Phenylbutyrate acts too slowly for emergency use.

• Pancreatic Insufficiency: Patients with conditions like chronic pancreatitis or cystic fibrosis may not produce enough lipase to break down the Glycerol Phenylbutyrate triglyceride. While not an absolute contraindication, it requires careful risk-benefit analysis and potentially the use of digestive enzyme replacements.
• Severe Hepatic Impairment: Because the liver is required to convert the drug into its active form (PAA), patients with end-stage liver disease may not benefit from the drug or may experience toxic buildup of intermediate metabolites.
• Severe Renal Impairment: Since the final product (PAGN) is excreted by the kidneys, those with kidney failure require extreme caution, as the drug's waste products will accumulate in the blood.

Patients who have had a negative reaction to Sodium Phenylbutyrate (Buphenyl) are likely to have a similar reaction to Glycerol Phenylbutyrate, as they share the same active metabolite. There is also a theoretical risk for patients with known sensitivities to other phenylalkanoic acids.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Glycerol Phenylbutyrate. Always ensure your medical ID or emergency records clearly state your UCD diagnosis and your current medications.

Glycerol Phenylbutyrate is classified as Pregnancy Category C (under the old FDA system). There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have shown that high doses of phenylacetic acid (PAA) can be neurotoxic to the developing fetus. However, untreated urea cycle disorders in the mother also pose a severe risk to both the mother and the fetus due to the risk of hyperammonemia during pregnancy and especially during the postpartum period. Healthcare providers must perform a careful risk-benefit analysis. If used during pregnancy, ammonia levels must be monitored very closely.

It is not known whether Glycerol Phenylbutyrate or its metabolites are excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants (specifically PAA neurotoxicity), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Glycerol Phenylbutyrate is approved for use in children of all ages, including newborns. It is often preferred in the pediatric population due to its lack of taste compared to sodium phenylbutyrate. Dosing is strictly based on Body Surface Area (BSA). In neonates, the drug must be used with extreme caution because their digestive enzymes (lipases) and liver metabolic pathways are not fully mature, which can affect how the drug is processed.

Clinical experience in patients aged 65 and older is limited. Geriatric patients are more likely to have decreased renal or hepatic function, which can affect the clearance of the drug's metabolites. Dosing should be conservative, starting at the lower end of the range.

In patients with impaired kidney function, the excretion of phenylacetylglutamine (PAGN) is reduced. While specific dose adjustments are not provided in the labeling, these patients require frequent monitoring of their metabolite levels to prevent accumulation.

Since the liver is the primary site for the conversion of phenylbutyrate to PAA and the subsequent conjugation with glutamine, hepatic impairment can significantly impact the drug's efficacy and safety. Patients with Child-Pugh Class B or C impairment may have higher levels of PAA, increasing the risk of neurotoxicity. Lower starting doses and frequent PAA/ammonia monitoring are required.

> Important: Special populations require individualized medical assessment. Pediatric and pregnant patients should only be managed by centers specializing in metabolic disorders.

Glycerol Phenylbutyrate is a nitrogen-binding agent. It is a pro-drug consisting of three molecules of phenylbutyrate esterified to a glycerol backbone. In the gastrointestinal tract, pancreatic lipases hydrolyze the triglyceride, releasing phenylbutyrate. Phenylbutyrate is then absorbed and undergoes beta-oxidation to form phenylacetic acid (PAA). PAA is the active moiety that conjugates with glutamine (which contains two nitrogen atoms) in the liver and kidneys to form phenylacetylglutamine (PAGN). PAGN is then excreted in the urine, providing an alternative pathway for nitrogen removal in patients who lack a functional urea cycle.

The primary pharmacodynamic effect is the reduction of plasma ammonia levels. The drug's effect is dependent on the availability of glutamine and the efficiency of the conjugation process. There is a direct correlation between the dose of Glycerol Phenylbutyrate and the amount of PAGN excreted in the urine. The time to reach a steady state of nitrogen removal is typically 3 to 7 days after starting the medication or changing the dose.

| Parameter | Value |

|---|---|

| Bioavailability | High (as metabolites) |

| Protein Binding (PAA) | 70% - 98% |

| Half-life (PAA) | 3 - 4 hours |

| Tmax (PAA) | 2 - 4 hours |

| Metabolism | Lipolysis -> Beta-oxidation -> Conjugation |

| Excretion | Renal (>80% as PAGN) |

• Molecular Formula: C33H38O6
• Molecular Weight: 530.65 g/mol
• Solubility: Insoluble in water; soluble in oils and organic solvents.
• Structure: A triglyceride where the three fatty acid positions are occupied by 4-phenylbutyrate.

Glycerol Phenylbutyrate is a nitrogen scavenger. It is closely related to sodium phenylbutyrate but differs in its chemical form (triglyceride liquid vs. sodium salt powder/tablet). It is the only triglyceride-based nitrogen scavenger currently FDA-approved for UCDs.